This increased reliance on device patents is consistent with observations from markets for other drug-device combinations, including inhalers for asthma and chronic obstructive pulmonary disease [19,40] and GLP-1 receptor agonist injector pens for diabetes and obesity [41]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.